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hematopoietic progenitor cell (HPC) mobilization in
myeloma (MM) and lymphoma has been associated with
reduction of mobilization failure. However, poor mobiliza-
tion (mobilopathy) still results in multiple days of collection,
increased resource utilization, morbidity and overall lower
numbers of HPCs. Mobilopathy is associated with exposure
to some chemotherapeutic agents, older age and female sex.
Ferraro et al recently postulated a diabetes-associated
mobilopathy. We analyzed mobilization patterns in a retro-
spective cohort of 221 patients undergoing mobilization
prior to autologous transplantation for MM (136) or
lymphoma (84).
Methods: Our algorithm for mobilization: A rescue (“just in
time”) plerixafor strategy was used after daily GCSF 10ug/kg
x5 days in those failing to develop adequate (<10
/uLCD34+HPC in peripheral blood (n¼8) or failing to mobi-
lize 1e6 CD34+HPC/kg on day 1of collection (n¼34). For
those predicted to be poor mobilizers based on prior mye-
lotoxic therapy or low platelet counts, 2 strategies were used
- planned Plerixafor after 5 days of GCSF or chemotherapy
followed by GCSF for those with no insurance coverage for
plerixafor.
Only 2 pts (<1%) failed to collect > 2e6 CD34+HPC/kg.
Major outcomes of interest for the remaining 219 pts were:
Collection of >2e6 CD34+HPC/kg on day1 and total CD
34+HPC collected over entire collection episode. Multivariate
regression models were used to evaluate potential predictors
of poormobilization. Diabetes requiring drug therapy (n¼32)
was considered in all models.
Results: Majority (75%) pts collected >2e6 CD34+HPC/kg on
day1. Among the 32 pts with diabetes, inadequate day 1
mobilization occurred in 40% (13/32) compared to 21% (40/
187) without diabetes. The use of HyperCVAD chemotherapy
was associated in 50% cases with inadequate CD34+HPC on
day1. In multivariate models, successful mobilization on
day1 was associated with absence of diabetes (odds ratio
2.49, P ¼ .04) and lack of HyperCVAD exposure (odds ratio
4.14, P ¼ .02).
Interestingly, although a signiﬁcant number received
“just in time” plerixafor, its use improved the total
CD34+HPC collection signiﬁcantly (odds ratio 2.98, 95% CI
P ¼ .0038) in all pts including 12 diabetic recipients.
In multivariate analysis, lower total yield of CD34+HPC/kg
was associated with increasing age (P¼0.0002) and the use
of conventional chemotherapy.
Conclusions: In our analysis of an unselected cohort of pts
undergoing mobilization, diabetes was an independent
predictor of slower mobilizationwith its effects mitigated by
plerixafor.
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Background: Health care institutions are identifying strate-
gies to reduce unnecessary testing, employ better utilization
of resources, and decrease patient risk. Both NCCN and IDSA
guidelines recommend reserving CXR for febrile neutropenic
(F+N) patients with respiratory symptoms. A retrospectivereview from 2010 showed that 11 of 237 (4.6%) Non Hodg-
kins Lymphoma and Multiple Myeloma SCT patients had
respiratory signs or symptoms when they presented with
F+N. Despite national guidelines, 97 of 237 (41%) patients
without symptoms also had a CXRwhen they presented with
F+N. None of the CXR in asymptomatic patients showed an
active pulmonary process. Based on these results and in
accordance with nationally recognized guidelines, we aimed
to reduce CXR in asymptomatic autologous F+N patients to
less than 10%.
Methods: A series of education sessions with clinical staff
including MDs, PAs, nocturnists and moonlighters were
implemented. Both oral andwrittenmaterials were prepared
for pass-off between the PAs and nocturnists. Study Pop-
ulation: We evaluated all patients admitted to the Dana-
Farber Cancer Institute Bone Marrow Transplant PA service
(BMT-PA) for autologous SCT between June 1, 2012 and Aug
31st 2012.
Results: During the ﬁrst three month study period, 69
patients were admitted to the BMT-PA service. Of the
admissions, 11 (23%) had a CXR without indication. Seven
CXR were ordered by PAs and 4 were ordered by nocturnist.
Conclusions:While we did not reach our target of 10% in the
ﬁrst Plan-Do-Study-Act (PDSA) Cycle, wewere able to reduce
the number of unnecessary CXR in asymptomatic F+N SCT
patients by close to 50%. This reduction includes a cost
savings of approximately $23,000, as well as a reduction in
radiation exposure, overall resource utilization, time off
protected air ﬂow units and patient inconvenience. Our
second PDSA cycle will include a clinician perception analysis
to identify why clinicians may feel it is necessary to order
a CXR in asymptomatic SCT patients with F+N, despite the
nationally recognized guidelines. We will provide ongoing
education sessions and continue toward our aim of less
than 10%.160
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Aim: This is a report of a study which explored how families
with children at home managed four to 12 months after an
adult family member was discharged from the hospital
following bone marrow/blood cell transplantation.
Methods: This study was a descriptive, qualitative, one-
point-in-time study. Content analysis in relation to the three
conceptual components of the Family Management Style
Framework was employed; inductive thematic analysis
determined the emergent conceptual dimensions present in
the data.
Results/Findings: The three conceptual components of the
Family Management Style Framework, (1) deﬁnition of the
situation, (2) management behaviors and (3) perceived
consequences, were validated as relevant for this sample
across all participants. New conceptual dimensions were also
present, inclusive of: recovery view, support base, ﬁnancial
picture, management domains, perceived consequences to
the whole family and perceived consequences to the dyad
relationships.
Conclusion: Implications for nursing practice include
a better understanding of how adult patients and their
families manage during the recovery phase. Future research
should include use of The Family Management Style Frame-
work throughout the entire transplant experience.
